Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company specializing in the development of treatments that aim to slow down the degenerative processes linked to aging and improve the functional outcomes of patients suffering from related diseases, today announces the success of its capital increase with maintenance of shareholders’ preferential subscription rights through the issue of Shares with Redeemable Share Subscription Warrants (ABSAR), the amount of which, issue premium included, amounts to at around €1.96 million.